Demographics, Clinical Characteristics, and Barriers to Care in Patientswith Dyslipidaemia in the Arabian Gulf Region: The Gulf ACTIONRegistry
INTRODUCTION: This study evaluates dyslipidaemia management in the Arabian Gulf region. METHODS: The multicentre, multinational longitudinal Gulf ACTION registry includes adults (≥18 years old) on lipid-lowering therapy (LLT) recruited from outpatient clinics at 14 tertiary care centres and 9 primary care clinics across five Arabian Gulf countries. RESULTS: A total of 2884 patients were enrolled (mean age 58±12 years); 63% were male. The median first follow-up was 7 (6-11) months, and the median second follow-up was 14 (12-23) months. Among the cohort, 52% of patients were very high risk, 21% of whom achieved their LDL-C target; 40% were high risk, 24% achieved their LDL-C target; 2% were moderate risk, 72% achieved their LDL-C target; and 6% were low risk, 78% achieved their LDL-C target. Only 24% of the overall cohort and 30% of the very high-risk group were treated with combination LLT. DISCUSSION: Similar to international data from the SANTORINI and INTERASPIRE studies, our study showed that only one-fourth of the very high-risk group and one-third of the high-risk group achieved their LDL-C targets. Potential reasons include lower use of combination therapy, poor health behaviors, and psychosocial factors. The variability in practice patterns across the Arabian Gulf and even among study sites is a limitation. CONCLUSION: Very high- and high-risk groups were less likely to achieve their LDL-C target. The low use of combination LLT, unhealthy lifestyle, and social factors in the Gulf region were the main reasons for such poor control. Strategies are needed to achieve current guideline-recommended LDL-C targets.
Authors
- Magdy Hassan
- Turky H. Almigbal (ORCID: https://orcid.org/0000-0002-8029-3071)
- Ali A. Youssef (ORCID: https://orcid.org/0000-0002-8063-8498)
- Riham A. ElToukhy (ORCID: https://orcid.org/0009-0009-6475-7903)
- Mustafa Al Hinai
- Mohammad Al Shehri
- Hanan Albackr (ORCID: https://orcid.org/0000-0001-9058-8204)
- Mohammad Amin (ORCID: https://orcid.org/0000-0002-2207-2967)
- Khalid F. AlHabib (ORCID: https://orcid.org/0000-0002-6692-3874)
- Mohammed A. Batais (ORCID: https://orcid.org/0000-0001-6766-7553)
- Hani Altaradi (ORCID: https://orcid.org/0000-0002-8422-1243)
- Wael Almahmeed (ORCID: https://orcid.org/0000-0003-0312-9910)
- Abdulhalim Jamal Kinsara (ORCID: https://orcid.org/0000-0002-6414-8720)
- K. Al Waili
- Manal Al-Kindi
- Mohammad Al Jarallah
- Naji Kholaif (ORCID: https://orcid.org/0009-0003-6914-0730)
- Nooshin Barzargani
- Shamsa Al Suwaidi
- Khalid Humaid Alrasadi
- Islam Ahmad
- Rajesh Rajan
- Ibrahim Al-Zakwani
Institutions
- Suez Canal University (EG)
- Dubai Health Authority (AE)
- Cleveland Clinic (US)
- Al-Azhar University (EG)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Faisal Specialist Hospital & Research Centre (SA)
- King Saud Medical City (SA)
- King Saud University (SA)
- Dubai Hospital (AE)
- Amiri Hospital (KW)
- Ider University (MN)
- Armed Forces Hospital (SA)
- Saud Al-babtain Cardiac Centre (SA)
- Al-Sabah Hospital (KW)
- Royal Hospital (OM)
- Sultan Qaboos University Hospital (OM)
- Cairo University hospitals (EG)
- National Guard Health Affairs (SA)
- Sultan Qaboos University (OM)
Publication Details
- Journal
- Current Vascular Pharmacology
- Published
- 2026-04-02
- DOI
- https://doi.org/10.2174/0115701611397165260302054720
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00